Study of efficacy of peripheral nerve blocks in lumbar disc herniation pai
- Conditions
- Health Condition 1: O- Medical and Surgical
- Registration Number
- CTRI/2021/09/036406
- Lead Sponsor
- AIIMS Rishikesh
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1.Age between 18-50 years of both sexes.
2.History of segmental low back pain of lumbar (L5) or sacral (S1) origin with radiation to unilateral lower limb below knee of less than 1-month duration.
3.Patients who are not the candidates for surgery.
4.Average pain score of >=4 on an 11-point NRS.
5.Tenderness over the concordant peripheral nerves (Gore sign +)
6.Magnetic resonance imaging (MRI) evidence of nerve root pain concordant with the side and level of clinical features.
1.Coagulopathy and/or patients on anticoagulants.
2.Infection at the site of injection.
3.Hypersensitivity to local anesthetic agent.
4.Evidence of significant progressive sensory or motor deficit, cauda-equina syndrome, H/O trauma, infection and cancer (Red flag signs).
5.Evidence of severe psychiatric illness.
6.History of previous backs surgery/epidural steroid injection.
7.History of any major comorbid medical conditions, those interfere with recording of study outcomes (any auto-immune diseases), multiple sclerosis, and pregnancy.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.Pain relief as assessed by Numerical Rating Scale (NRS) on a scale of 1-10 immediately after the procedure, at 2 weeks and at 2 and 3 months after the procedureTimepoint: 1.Pain relief as assessed by Numerical Rating Scale (NRS) on a scale of 1-10 immediately after the procedure, at 2 weeks and at 2 and 3 months after the procedure
- Secondary Outcome Measures
Name Time Method 1.Changes in biomarkers of pain before and after distal nerve block (high sensitive C reactive protein, tumor necrosis factor-alpha, interleukin 6, interleukin-4) <br/ ><br>2.Physical functioning as assessed by Roland Morris Questionnaire (Annexure â??II) <br/ ><br>3.Global Perceived Effects (Annexure-III) <br/ ><br>4.To assess spontaneous reporting of adverse effects and the incidence of complications due to the procedure. <br/ ><br>Timepoint: Changes in biomarkers of pain before and after distal nerve block